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Purpose/Objective: Cambridge University Hospitals (CUH) has been 
routinely treating patients with Head & Neck Squamous Cell 
Carcinoma with Image-Guided/Intensity Modulated Radio Therapy 
(IG/IMRT) using helical arc therapy (HAT) since 2008. We compared 
outcomes for patients with oropharyngeal cancer treated using HAT 
with historical control cohorts treated using conformal radiotherapy 
techniques or 'step and shoot' IMRT delivered on a conventional linear 
accelerator. 
Materials and Methods: We retrospectively reviewed patients treated 
radically with radiotherapy for primary oropharyngeal squamous cell 
carcinoma at CUH between April 2002 and April 2010 (recurrent 
disease, non-squamous pathology or palliative treatment were 
excluded). 183 patients were identified for whom sufficient data 
could be demonstrated, 141 (77%) were male and 42 (23%) female. 
Median age at diagnosis was 58 years (range 30 - 83). Commonest site 
for primary tumour was tonsil (95 patients, 51.9%) followed by tongue 
base (68 patients, 37.2%). Most patients treated were stage 3 (35 – 
19.2%) or stage 4 (127 - 69.7%). 62 patients underwent neck surgery - 
59 patients (32.2%) had unilateral neck dissection, 3 (1.6%) had 
bilateral nodal clearance. 95 patients (52%) had concomitant 
chemoradiotherapy (cisplatin or cetuximab) and only 3 patients (1.6%) 
had induction chemotherapy. Over 90% of patients were treated to 68 
Gy in 34 daily fractions over seven weeks. Other schedules, each used 
for 5 patients or less, included 70 Gy in 35 #, 65 Gy in 30 # and 55 Gy 
in 20 #.  Conformal radiotherapy was used for 111 (60.6%) patients 
between 2002 & 2008, 17 (9.3%) had IMRT delivered on a conventional 
linac (2007-09) and 55 patients (30.1%) were treated with helical arc 
therapy (2008-10). The patients treated by each method had similar 
distributions of age, disease site and stage, and similar numbers 
underwent neck surgery. Increasing use of concomitant 
chemoradiotherapy was evident (41.8% in conformal group, 64.7% in 
IMRT group and 74.5% in HAT group).  
Results: Median follow-up was 4.4 years and for the 'conformal RT', 
'IMRT' and 'HAT' groups was 5.6, 3.7 and 3.2 years, respectively. 
Kaplan-Meier survival probability estimates for recurrence-free 
survival and overall survival at two years showed improved results for 
patients treated with HAT compared to patients treated using our 
prior techniques. HAT also resulted in a lower ratio of loco-regional 
recurrence to distant relapse suggesting effective primary disease 
control. T-stage was a strong prognostic indicator and is associated 





Conclusions: Local control and overall survival statistics for patients 
with oropharyngeal cancer treated at Cambridge University Hospitals 
using HAT and concomitant chemotherapy were better than for 
historic controls. Tumour T-Stage at diagnosis was a strong prognostic 
indicator for both disease-free and overall survival at two years. 
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Purpose/Objective: To investigate the prognostic effect of tumor 
volume on patients with advanced nasopharyngeal carcinoma (NPC). 
Materials and Methods: From February 2000 to June 2006, a total of 
181 patients with biopsy-proven NPC, no distant metastasis, and 
available pre-treatment magnetic resonance imaging were 
retrospectively reviewed. Most of the patients (95.6%) had stage III/IV 
diseases. All patients were treated by 10-weekly neoadjuvant 
chemotherapy and radiotherapy. We delineated the contour of the 
primary tumor, retropharyngeal and neck nodes. The tumor volume 
was calculated by the EclipseTM treatment planning software. PTV, 
NTV, TTV indicated tumor volumes of primary site, regional nodes, 
and total tumor. The end-points included subsequent distant failure 
rates, nasopharynx failure-free survival (NPFFS), distant metastasis 
failure-free survival (DMFFS), relapse-free survival (RFS) and overall 
survival (OS). 
Results: After a minimal follow-up of 60 months for living patients, 
there were 55 failures – 8 in primary, 3 in regional, 34 in distant, 2 in 
primary+ regional, 6 in primary+ distant, 1 in regional+ distant, and 1 
in primary+ regional + distant sites. The PTV and NTV were positively 
correlated withT-stage and N-stage (P<0.0001). The range of TTV was 
7.99 – 323.65 cm3, with a median of 52.33 cm3and a mean of 66.45 
cm3.The median TTV of stage II, III, and IV were 28.28, 38.81, and 
68.06 cm3respectively (P<0.0001). PTV affects NPFFS (P=0.0252) and 
OS (P=0.0281) significantly. NTV affects DMFFS (P<0.0001) and OS 
(P=0.0028)significantly. Patients with tumor relapse had significantly 
higher TTV than those without relapse (median 45.95 vs. 69.53 cm3, 
P<0.0001). The tumor relapse rates between the patients with TTV ? 
and < 54.96 cm3 were 47.0% (39/83) and 16.3%(16/98), respectively 
(P<0.001).The distant failure rates between the patients with TTV ? 
and < 54.96 cm3 were 37.3% (31/83) and 11.2%(11/98), respectively 
(P<0.001).The rates of 7-year DMFFS, RFS, and OS in patients with TTV 
? 54.96 cm3 were significantly lower than those with TTV < 54.96 
cm3.The TTV also affect NPFFS with a borderline significance 
(P=0.0553). 
Conclusions: PTV is correlated with T-stage and affects NPFFS and OS. 
NTV is correlated with N-stage and affects DMFFS and OS. TTV is 
correlated with overall stage and has a significant effect on tumor 
relapses and patient survivals in advanced NPC. 
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Purpose/Objective: To analyse the patterns of locoregional (LR) 
failure in patients (pts) with head-and-neck cancer (HNC) treated with 
intensity-modulated radiotherapy (IMRT) aiming to spare the parotid 
glands (PG) the submandibular glands (SMG) and the accessory salivary 
glands represented by the oral cavity (OC). 
Materials and Methods: Between September 2009 and August 2011, 70 
consecutive pts with squamous cell HNC treated with definitive 
bilateral neck IMRT were included. The disease was stage III-IV and 
stage I-II in 77% and 23% of pts respectively. The primary tumor site 
was the OC (8 pts), oropharynx (31 pts), hypopharynx (17pts), larynx 
(10 pts), nasopharynx (3 pts), and 1 patient had unknown primary 
tumor. A simultaneously integrated boost (SIB) technique with 3 dose 
levels (PTV70-66, PTV63-60, PTV56-54 Gy) was used. 69% of pts 
received a concomitant treatment. The FDG-PET and CT scan of the 
recurrence were fused with the initial planning CT. Contours of the 
failure volumes (Vf) were defined taking into account all clinical 
examination, radiological imaging and histological information. 
Failures were categorized as 'in-field' if more than 95% of the Vf was 
covered by 95% of the prescription dose, 'marginal' if 20% to 95% of the 
Vf was encompassed by 95% of the prescription dose, and 'out-of-field' 
if less than 20% was contained within the 95% dose. Dose-volume 
histograms were calculated to analyse the dose received by Vf. The 
doses delivered in the salivary glands and OC spared were assessed. 
Xerostomia was assessed according to Radiation Therapy Oncology 
Group (RTOG) criteria. 
Results: With a median follow-up of 20 months (range: 6-35), the 2-
years LR control and overall survival rates were 76.5% (95% confidence 
